Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC)
Pancreatic adenocarcinoma (PDAC) is a highly aggressive cancer with a high chance of recurrence, limited treatment options, and poor prognosis. A recent study has classified pancreatic cancers into four molecular subtypes: (1) squamous, (2) immunogenic, (3) pancreatic progenitor and (4) aberrantly differentiated endocrine exocrine. Among all the subtypes, the squamous subtype has the worst prognosis. This study aims to utilize large scale genomic datasets and computational systems biology to identify potential drugs targeting the squamous subtype of PDAC through combination therapy. Using the transcriptomic data available from the International Cancer Genome Consortium, Cancer Cell Line Encyclopedia and Connectivity Map, we identified 26 small molecules that could target the squamous subtype of PDAC. Among them include inhibitors targeting the SRC proto-oncogene (SRC) and the mitogen-activated protein kinase kinase 1/2 (MEK1/2). Further analyses demonstrated that the SRC inhibitors (dasatinib and PP2) and MEK1/2 inhibitor (pimasertib) synergized gemcitabine sensitivity specifically in the squamous subtype of PDAC cells (SW1990 and BxPC3), but not in the PDAC progenitor cells (AsPC1). Further analysis revealed that the synergistic effects are dependent on SRC or MEK1/2 activities, as overexpression of SRC or MEK1/2 completely abrogated the synergistic effects SRC inhibitors (dasatinib and PP2) and MEK1/2 inhibitor (pimasertib). In contrast, no significant toxicity was observed in the MRC5 human lung fibroblast and ARPE-19 human retinal pigment epithelial cells. Together, our findings suggest that combinations of SRC or MEK inhibitors with gemcitabine possess synergistic effects on the squamous subtype of PDAC cells and warrant further investigation.
KeywordsPancreatic cancer Connectivity map Drug combination Dasatinib PP2 Pimasertib
This work was supported in part by the Malaysia Ministry of Education Fundamental Research Grant Scheme (FRGS/1/2017/SKK08/IMU/03/1 to MCW, FFLC and COL; FRGS/1/2016/SKK08/IMU/01/1 to LWH) and the IMU Research Fund (BP I-01/14(05)2017; JLE, PNG, CYL and YJT).
Compliance with ethical standards
Conflict of interest
The authors report no conflicts of interest pertaining to this study.
Research involving human participants and/or animals
No human participants and/or animals was involved in this study.
No informed consent was required for this study.
- 10.Vennin C, Murphy KJ, Morton JP, Cox TR, Pajic M, Timpson P. (2017) Reshaping the tumor stroma for treatment of pancreatic cancer. Gastroenterology 154:820–838Google Scholar
- 24.Low SY, Choo HL, Tan BS, Tiong KH, Khoo ASB, Leong CO (2011) Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells. 5th International Symposium on Nasopharyngeal carcinoma, Penang, MalaysiaGoogle Scholar
- 45.Bartscht T, Rosien B, Rades D et al (2015) Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of smad signalling: implications for in vivo mode of action. Mol Cancer 14:199CrossRefPubMedPubMedCentralGoogle Scholar
- 55.Martinelli E, Troiani T, D’Aiuto E et al (2013) Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Int J Cancer 133:2089–2101CrossRefPubMedGoogle Scholar